for an upfront payment of $45m big pharma can save themselves not only the cost of developing the drug ($45m to date), but also the 7 years of development @rljThe MD has said that its time to realise the value of the investment in AD-214. So, what is the value of that investment to date? For a biotech located in the US, one might conservatively imagine that getting a drug candidate in readiness for Phase 2 would be north of US$100m. According to the balance sheet for AdAlta as at 31 Dec 2023, it appears that the figure - as represented by accumulated losses - is AUD$45m.
By chance, IPF assets - according to the Gems presentation - command upfront license payments of more than US$45m. Neat numerical symmetry. Lets call the currency difference between USD and AUD as the initial return on investment, following the recoupment of investment to date.
I know its just playing with numbers but its kind of funny how the answer between the company balance sheet and the corporate presentation is 45. Its close enough to another well known number so lets call it the Hitchhikers Guide to Investment Return.
(20min delay)